Short or Put ConsiderationOne bad Mamma Jamma I'm buying Puts. Follow the Trendline down; Pretty self Explanatory.
−0.2ILS
−223.55 MILS
17.70 MILS
1.08 B
About BIOLINE RX
Sector
CEO
Philip Adam Serlin
Headquarters
Modi'in
Website
Employees (FY)
38
Founded
2003
ISIN
IL0011015182
FIGI
BBG000D3FWW6
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
$BLRX is gonna fall todayPupm&Dump trading strategy idea.
$BLRX is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $3,66;
stop-loss — $3,82;
take-profit — $3,36.
Do not view th
bulls on a tear over heredamn, comin' in hot. The 30s charts requires some steel cajones. good trading over here today... 🤙🏽
real sleeperI honestly believe this stock is a real sleeper. analysts predict a 247% increase from current levels. I would keep an eye on this one. Tight squeeze showing as it continues to consolidate. reminder, this stock has been consolidating for a while now and the longer the consolidation the bigger the pu
Bioline Rx ---- Descending Wedge FormationWe have a possible setup forming on BLRX, in that it does seem to be filling out the descending wedge to the downside. Let's watch for a break to the upside and a confirmation retest of the trend line as well. This is not trading advice.
BLRX Been holding up pretty damn welll. 3$ level is first main support. If falls below that 275 has been well know support. Golden cross incoming on weekly. Short term bearish mid-long term bullish. If waiting for breakout , long long is founded supporrt above 4.27
BLRX 2/7/2020Analysis:
Daily chart, initially price was in sideways range for 225 days between 1.17 - 2.34 areas. Price has since broke out of that range and has been bouncing between 2.34 - 3.07 areas. 2.34 price was resistance turned support area. Price has also been above & steadily supported by 200 MA, sign
$BLRX is gonna fall todayPupm&Dump trading strategy idea.
$BLRX is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $4,39;
stop-loss — $4,69;
take-profit — $3,
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BLRX is 16.7 ILA — it has decreased by 2.34% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange BIOLINE RX stocks are traded under the ticker BLRX.
BIOLINE RX is going to release the next earnings report on May 22, 2024. Keep track of upcoming events with our Earnings Calendar.
BLRX stock is 7.27% volatile and has beta coefficient of 0.95. Check out the list of the most volatile stocks — is BIOLINE RX there?
One year price forecast for BIOLINE RX has a max estimate of 5.2 ILA and a min estimate of 1.6 ILA.
BLRX earnings for the last quarter are −0.08 ILA per share, whereas the estimation was −0.05 ILA resulting in a −42.15% surprise. The estimated earnings for the next quarter are −0.05 ILA per share. See more details about BIOLINE RX earnings.
BIOLINE RX revenue for the last quarter amounts to 0 ILA despite the estimated figure of 0 ILA. In the next quarter revenue is expected to reach 544.64 K ILA.
Yes, you can track BIOLINE RX financials in yearly and quarterly reports right on TradingView.
BLRX stock has fallen by 12.11% compared to the previous week, the month change is a 41.61% fall, over the last year BIOLINE RX has showed a 33.47% decrease.
BLRX net income for the last quarter is −53.07 M ILS, while the quarter before that showed −59.97 M ILS of net income which accounts for 11.52% change. Track more BIOLINE RX financial stats to get the full picture.
Today BIOLINE RX has the market capitalization of 200.25 M, it has decreased by 6.09% over the last week.
No, BLRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BLRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOLINE RX stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 38.00 employees. See our rating of the largest employees — is BIOLINE RX on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOLINE RX technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOLINE RX stock shows the strong sell signal. See more of BIOLINE RX technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BIOLINE RX future price: according to them, BLRX price has a max estimate of 517.13 ILA and a min estimate of 160.06 ILA. Read a more detailed BIOLINE RX forecast: see what analysts think of BIOLINE RX and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOLINE RX EBITDA is −153.94 M ILS, and current EBITDA margin is −866.81%. See more stats in BIOLINE RX financial statements.